Randomized phase III trial of Docetaxel versus docetaxel plus S-1 for second-line treatment of non-small cell lung cancer (NSCLC)
Phase 3
- Conditions
- Advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000001826
- Lead Sponsor
- The Japan-multinational Trial Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 860
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with serious infections or suspected infections with fever. 2) Pregnant or lactating women 3) Active concomitant malignancy 4) sever allergy 5) Active ineterstitial pneumonitis 6) The prior treatment is a case only of the molecular-targeted agent. 7) Symptomatic brain metastasis 8) History of using 5-FU or docetaxel 9) Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method